Thermo Fisher Scientific 8-K

PositiveEarningsGuidance deferred to the call

Strengthening customer activity supports organic growth; microbiology business divestiture announced.

Filed 2026-07-23 06:04 ET

Summary

Q2 2026 results with updated FY2026 guidance to be provided on the earnings call. Revenue grew 10%, including 5% organic growth; GAAP diluted EPS rose 9% and adjusted EPS rose 13%. Thermo Fisher cited strengthening customer activity, repurchased $1.0B of stock during the quarter and announced the divestiture of its microbiology business.

Key Figures

Metric Q2 2026 Q2 2025 Y/Y
Revenue $12.0B $10.9B 10%
GAAP operating income $2.09B $1.83B 14%
Adjusted operating income, non-GAAP $2.74B $2.38B 15%
Net income attributable to Thermo Fisher Scientific Inc. $1.74B $1.62B 7%
Adjusted net income, non-GAAP $2.24B $2.03B 11%
Diluted EPS, GAAP $4.68 $4.28 9%
Adjusted EPS, non-GAAP $6.03 $5.36 13%
Net cash provided by operating activities $2.13B $1.40B 52%
Free cash flow, non-GAAP $1.68B $1.11B 52%
  • Revenue growth included 5% from acquisitions and 1% from currency translation; organic revenue growth was 5%.
  • For 6M 2026, revenue was $23.0B vs $21.2B (+8%); diluted EPS was $9.10 vs $8.26 (+10%), and adjusted EPS was $11.47 vs $10.51 (+9%). Operating cash flow was $3.32B vs $2.12B, and free cash flow was $2.50B vs $1.48B.
  • Stock repurchases were $1.0B in Q2 and $4.0B for 6M, vs $2.0B for 6M 2025. At 6/27/2026, cash and cash equivalents were $4.06B; total short-term obligations and current maturities plus long-term obligations, at carrying value, were $42.5B. The company used $8.87B net of cash acquired for acquisitions during 6M.

Guidance

Guidance to be given on the earnings call.

Investor Takeaways

  • Watch the updated FY2026 guidance on the earnings call for the company’s outlook following the stronger Q2 results.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback